

SHORT REPORT

Open Access

Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans

Simone Onur¹, Petra Niklowitz², Gunnar Jacobs³, Ute Nöthlings⁴, Wolfgang Lieb³, Thomas Menke² and Frank Döring^{1*}

Abstract

Background: The reduced form of Coenzyme Q₁₀ (CoQ₁₀), ubiquinol (Q₁₀H₂), serves as a potent antioxidant in mitochondria and lipid membranes. There is evidence that Q₁₀H₂ protects against oxidative events in lipids, proteins and DNA. Serum gamma-glutamyltransferase (GGT) activity is associated with cardiovascular diseases. In a physiological range, activity of GGT is a potential early and sensitive marker of inflammation and oxidative stress. In this study, we first examined the relationship between CoQ₁₀ status and serum GGT activity in 416 healthy participants between 19 and 62 years of age in a cross-sectional study (cohort I). In the second step, 53 healthy males (21–48 years of age; cohort II) underwent a 14-day Q₁₀H₂ supplementation (150 mg/d) to evaluate the effect of Q₁₀H₂ supplementation on serum GGT activity and *GGT1* gene expression.

Findings: There was a strong positive association between CoQ₁₀ status and serum GGT activity in cohort I. However, a gender-specific examination revealed differences between male and female volunteers regarding the association between CoQ₁₀ status and serum GGT activity. Q₁₀H₂ supplementation (cohort II) caused a significant decrease in serum GGT activity from T₀ to T₁₄ (p < 0.001). *GGT1* mRNA levels declined 1.49-fold after Q₁₀H₂ supplementation. Of note, other liver enzymes (i.e., aspartate aminotransferase, AST) were not affected by Q₁₀H₂ supplementation.

Conclusions: CoQ₁₀ level is positively associated with serum GGT activity. Supplementation with Q₁₀H₂ reduces serum GGT activity. This effect might be caused by gene expression. Overall, we provide preliminary evidence that higher Q₁₀H₂ levels improve oxidative stress via reduction of serum GGT activity in humans.

Trial registration: Current Controlled Trials ISRCTN26780329.

Keywords: Coenzyme Q₁₀, Ubiquinol, Gene expression, Supplementation study, Liver enzymes, Oxidative stress, Antioxidants

Background

Coenzyme Q₁₀ (CoQ₁₀) is a redox molecule that is present in the membranes of almost all human tissues [1]. CoQ₁₀ is a lipophilic molecule that is synthesized within the mitochondrial inner membrane and is essential for the respiratory transport chain. As an antioxidant in cell membranes, CoQ₁₀ is important for the maintenance of the cellular redox homeostasis [2]. Furthermore, CoQ₁₀ is necessary for pyrimidine biosynthesis while also being a cofactor for uncoupling proteins [3]. It has also been identified as a

modulator of gene expression [4-6], inflammatory processes [7-9] and apoptosis [10,11]. The reduced form of CoQ₁₀, ubiquinol (Q₁₀H₂), serves as a potent antioxidant in mitochondria and lipid membranes as well as a regenerator of other lipid soluble antioxidants [12]. In recent years, there has been growing evidence of the protective role of Q₁₀H₂ in oxidative events in lipids, proteins and DNA, a concept known as oxidative stress [13,14].

The liver enzyme gamma glutamyltransferase (GGT) is located at the outer surface of the plasma membrane where it facilitates the synthesis of the antioxidant glutathione (GSH) [15]. GGT initiates the degradation of extracellular GSH by hydrolyzing the γ -glutamyl-cysteine bond in GSH [16]. The regulation of GGT is complex. Human GGT is

* Correspondence: sek@molprev.uni-kiel.de

¹Institute of Human Nutrition and Food Science, Division of Molecular Prevention, Christian Albrechts University Kiel, Heinrich-Hecht-Platz 10, 24118 Kiel, Germany

Full list of author information is available at the end of the article

encoded by a multi-gene family consisting of at least seven genes. One of these genes, *GGT1*, encodes for the active enzyme present in human tissues [17]. Serum GGT has long been regarded as a marker for excessive alcohol consumption or liver disturbances in clinical practice [18]. However, it has recently been shown that serum GGT is also a marker for the development of cardiovascular disease, hypertension, stroke and type 2 diabetes mellitus and their complications independent from alcohol consumption [19-22]. Further studies provide evidence that serum GGT activity is a potential early and sensitive marker of inflammation and oxidative stress [23-25]. Of note, this effect was only found in the physiological range of GGT activity.

It is known that oxidative stress can be attenuated by $Q_{10}H_2$ [13,14]. Because serum GGT is a putative marker of oxidative stress, we examined (i) the relationship between CoQ_{10} status and serum GGT activity in a sample of 416 healthy volunteers (cohort I) and (ii) the effect of $Q_{10}H_2$ supplementation on serum GGT activity and *GGT1* gene expression in an intervention cohort of 53 healthy male volunteers (cohort II).

Methods

Study populations

Cohort I – cross-sectional study

The study sample was part of the PopGen control cohort. The original study design is described elsewhere [26]. The study population consisted of 416 healthy blood donors between 19 and 62 years old with a mean body mass index (BMI) of 26.1 kg/m² (standard deviation, 4.7 kg/m²). A total of 53% were males. All study participants were phenotyped with respect to anthropometric, cardiovascular and metabolic traits in a standardized fashion (details below). Blood samples were taken after an overnight fast and immediately centrifuged. Serum samples were stored at -80°C until CoQ_{10} was analyzed. The participants had no history of gastrointestinal, hepatic, cardiovascular or renal diseases; maintained usual nutrition habits; and were non-smokers or occasional smokers. The study was approved by the ethics committee of the Medical Faculty of Kiel University and was consistent with the Helsinki Declaration. All volunteers gave written informed consent. Recruitment of study probands as well as data and biosample collection were performed using the PopGen biobank, Kiel, Germany.

Cohort II – supplementation study

The sample characteristics and study design have been described previously [27]. Briefly: 53 healthy male volunteers between 21 and 48 years of age received 150 mg of the reduced form of CoQ_{10} ($Q_{10}H_2$, ubiquinol, KANEKA Corporation, Japan) daily in the form of three capsules à 50 mg $Q_{10}H_2$ taken with each main meal (breakfast, lunch and dinner) for 14 days. Fasting blood samples were taken before (T_0) and after (T_{14})

supplementation. The participants had an average BMI of 24.1 ± 2.5 kg/m²; had no history of gastrointestinal, hepatic, cardiovascular or renal diseases; maintained usual nutrition habits; and were non-smokers or occasional smokers. The study was approved by the ethics committee of the Medical Faculty of Kiel University, Germany, and was consistent with the Helsinki Declaration. All volunteers gave written informed consent.

CoQ₁₀ analysis

CoQ_{10} analysis was based on the method of high-pressure liquid chromatography (HPLC) with electrochemical detection and internal standardization using ubihydroquinone-9 and ubiquinone-9 as standards, as described elsewhere [28]. 100 µL plasma aliquots were used in both cohorts to perform robust HPLC analysis with repeats, when indicated.

Anthropometric measurements

Body weight was measured in underwear on a manual scale to the nearest 100 g (Seca, Hamburg, Germany). Height was measured without shoes on a stadiometer (Seca, Hamburg, Germany) to the nearest 0.5 cm.

Clinical parameters, metabolic parameters and gene expression

Blood pressure measurements were obtained while the subject was in a seated position, using a standard manual sphygmomanometer. A fasting venous blood sample was obtained from all study participants and analyzed following standard procedures. Briefly, blood glucose was analyzed using a hexokinase method (Gluco-quant, Roche Diagnostics, Mannheim, Germany). Cholesterol and triacylglycerol concentrations were measured enzymatically by hydrolyzing cholesterol ester and triacylglycerol to cholesterol and glycerol, respectively. HDL cholesterol (HDL-C) was measured in the supernatant after precipitation of lipoproteins (kits and standards by Konelab Corporation, Espoo, Finland). The liver enzymes gamma glutamyltransferase (GGT) and aspartate aminotransferase (AST) were analyzed according to the recommendations of the International Federation of Clinical Chemistry (IFCC) from 1983 (confirmed and extended in 2002), including optimization of substrate concentrations and employment of NaOH, glycylglycine buffer and sample start. Plasma C-reactive protein (CRP) concentrations were measured using a latex enhanced nephelometric assay run on a BN II hematology analyzer (Dade Behring, Marburg, Germany). Microarray experiments using the Affymetrix human genome U133 plus 2.0 GeneChip® were performed as previously described [5] with RNA samples from CD14-positive monocytes obtained from three volunteers before (T_0) and after (T_{14}) supplementation with ubiquinol.

Statistics


Statistical analyses were performed with SPSS (Statistical Package for the Social Sciences) 20.0 software (SPSS GmbH Software, München, Germany). Before statistical analysis, normal distribution of the parameters was tested. Gender-related differences in anthropometric and metabolic parameters and differences between subjects with normal and elevated GGT activity were analyzed using a nonparametric Mann–Whitney *U*-test. Differences from supplementation regarding two time-points (T_0 vs. T_{14}) were tested using a paired Student's *t*-test. The level of statistical significance was set at $p < 0.05$.

Findings

Study population – cohort I

We examined 416 healthy volunteers in a cross-sectional study. As shown in Figure 1, more than 90% of the study population had normal activity of serum GGT ($<50/40$ U/l male/female), whereas 9.1% ($n = 21$) of male and 6.1% ($n = 12$) of female volunteers had increased serum GGT activity. Because serum GGT activity is postulated to be a marker of oxidative stress in its normal range, study subjects with elevated serum activity of GGT were excluded.

The characteristics of cohort I are depicted in Table 1. Study subjects were healthy but slightly overweight (mean BMI 26.2 ± 4.7 kg/m²) with a mean age of 40.0 years. On average, values of CoQ₁₀ status and pro-inflammatory CRP were in a normal range. Components of metabolic syndrome were below the thresholds



defined by the Adult Treatment Panel III (ATPIII). Gender-stratified analyses revealed significant differences between males and females. Compared to women, men had higher BMI, total CoQ₁₀, ubiquinol, GGT activity, blood pressure, triglycerides, total and LDL-cholesterol and glucose, whereas women had higher CRP- and HDL-cholesterol levels than men. Additionally, female volunteers tended to have a higher CoQ₁₀-redox state (% oxidized CoQ₁₀ in total CoQ₁₀; $p = 0.054$) compared to males.

CoQ₁₀ is related to serum GGT activity by gender

We conducted a correlation analysis to evaluate the relationship between CoQ₁₀ status and serum GGT activity. As shown in Table 2, levels of total CoQ₁₀, ubiquinol, ubiquinone (oxidized form of CoQ₁₀; all $p < 0.001$) and redox state ($p < 0.05$) were positively correlated with serum GGT activity in the whole study sample. Analyses conducted separately by gender revealed a stronger positive correlation between total CoQ₁₀ level and serum GGT activity in men ($p < 0.001$) than in women ($p < 0.05$). Additionally, the reduced form of CoQ₁₀, ubiquinol, was positively associated with serum GGT activity ($p < 0.001$) in men but not in women. In contrast, the oxidized form of CoQ₁₀, ubiquinone, had a stronger positive correlation with serum GGT activity in women ($p < 0.001$) than in men ($p < 0.01$), and interestingly, there was a highly significant positive correlation between the redox state and serum GGT activity solely in women ($p < 0.001$). These results are shown in Figure 2, which depicts the positive linear association between CoQ₁₀ status and serum GGT activity in the whole population as well as in gender-specific sub-groups. With the exception of the CoQ₁₀ redox state, all parameters of CoQ₁₀ status were positively correlated with serum GGT activity. However, there were gender-specific differences. While the data from men showed a stronger positive relationship between levels of both total CoQ₁₀ (Figure 2A) and ubiquinol (Figure 2B) and serum GGT activity compared with the relationship found in women, there was only a small gender-related difference in the R^2 of ubiquinone and serum GGT activity (Figure 2C). In addition, women but not men had a strong positive association between the redox state of CoQ₁₀ and the activity of serum GGT activity (Figure 2D).

CoQ₁₀ is not associated with other liver-related enzymes (i.e., AST)

To evaluate the specificity of the relationship between CoQ₁₀ and GGT, we also performed a correlation analysis with the parameters of CoQ₁₀ status and serum aspartate aminotransferase activity (AST). As shown in Table 3, there were no significant associations between CoQ₁₀ status and serum AST activity.

Table 1 Basic characteristics of cohort I (subsample of the popgen control cohort)

	All (n = 383)	Males (n = 199)	Females (n = 184)
Age [years]	40.0 ± 10.9	40.5 ± 10.5	38.7 ± 11.2
Body mass index [kg/m ²]	26.2 ± 4.7	26.2 ± 3.9	25.7 ± 5.2**
CoQ ₁₀ [μmol/l]	0.94 ± 0.34	0.96 ± 0.36	0.87 ± 0.29*
Ubiquinol [μmol/l]	0.12 ± 0.05	0.12 ± 0.04	0.11 ± 0.04
Ubiquinone [μmol/l]	0.82 ± 0.30	0.84 ± 0.33	0.76 ± 0.25*
CoQ ₁₀ redox state [%]	12.5 ± 2.6	12.2 ± 2.5	12.7 ± 2.7
Gamma GT [U/l]	18.8 ± 8.4	22.5 ± 8.3	14.7 ± 6.3***
C-reactive protein[mg/l]	2.24 ± 3.36	1.58 ± 1.92	2.47 ± 3.00***
Systolic BP [mm Hg]	130 ± 16	134 ± 15	125 ± 14***
Diastolic BP [mm Hg]	78 ± 9	80 ± 9	75 ± 8***
Triglycerides [mg/dl]	121.9 ± 73.3	132.1 ± 76.1	100.5 ± 50.3***
Cholesterol [mg/dl]	193.3 ± 35.7	194.3 ± 39.8	190.3 ± 28.8
LDL-cholesterol [mg/dl]	116.6 ± 32.5	122.6 ± 34.7	108.0 ± 26.1***
HDL-cholesterol [mg/dl]	62.1 ± 16.7	54.8 ± 13.4	71.1 ± 16.1***
Glucose [mg/dl]	92.5 ± 10.7	94.1 ± 11.3	90.1 ± 9.7***

CoQ₁₀ = Coenzyme Q₁₀; Gamma GT = gamma glutamyltransferase; BP = blood pressure; LDL = low density lipoprotein, HDL = high density lipoprotein. Data are presented as mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001 significant differences between sexes, Mann-Whitney U-test.

Q₁₀H₂ Supplementation study – cohort II

To examine whether Q₁₀H₂ supplementation influences the activity of GGT and AST, we re-analyzed our human intervention study [27]. Within this study, 53 healthy male volunteers were supplemented with 150 mg ubiquinol per day for two weeks. Table 4 shows the basic characteristics of the study population (cohort II). The study subjects were between 21 and 48 years of age with a mean BMI of 24.1 ± 2.5 kg/m². All parameters regarding CoQ₁₀ status, CRP status as well as the parameters of metabolic syndrome defined by ATPIII were within a normal range.

To investigate the effects of Q₁₀H₂ supplementation, fasting blood samples were taken before (T₀) and after (T₁₄) supplementation with Q₁₀H₂. As described previously, plasma CoQ₁₀ levels increased more than fourfold from T₀ to T₁₄ (0.96 ± 0.31 pmol/μl to 4.60 ± 1.55 pmol/μl, p < 0.001, data not shown) whereas the redox state decreased significantly from 7.47 ± 0.97% to 5.95 ± 0.91% (p < 0.001; data not shown) [27].

Q₁₀H₂ supplementation reduces serum GGT activity and mediates down regulation of GGT1 mRNA

Figure 3A shows a significant decrease of GGT activity from T₀ to T₁₄ (20.49 ± 10.36 U/l to 17.79 ± 7.68 U/l; p < 0.001). In contrast, we found no alteration of AST activity in response to Q₁₀H₂ supplementation (Figure 3B). To investigate whether the effect on GGT activity is also detectable on gene expression level, the mRNA steady state level of both *GGT1* (GGT) and *GOT2* (AST) were determined in CD14-positive monocytes of three subjects before and after Q₁₀H₂ supplementation. Indeed, we found that Q₁₀H₂ supplementation reduced the *GGT1* mRNA level with a fold change of -1.49 (Figure 3C) and the *GOT2* mRNA level with a fold change of -1.34 (Figure 3D).

Discussion

Association between CoQ₁₀ status and serum GGT activity
 Highly elevated serum GGT is a well-known marker of alcohol consumption, alcoholic liver diseases, and cholestasis

Table 2 Correlation coefficients between Coenzyme Q₁₀ (CoQ₁₀) status and gamma glutamyltransferase (GGT)

	GGT		
	All (n = 383)	Males (n = 220)	Females (n = 196)
CoQ ₁₀ [μmol/l]	0.276***	0.290***	0.161*
Ubiquinol [μmol/l]	0.258***	0.267***	0.137
Ubiquinone [μmol/l]	0.240***	0.217**	0.290***
CoQ ₁₀ redox state [%]	0.105*	0.089	0.273***

*p < 0.05; **p < 0.01, ***p < 0.001.




Table 3 Correlation coefficients of Coenzyme Q₁₀ (CoQ₁₀) status and aspartate aminotransferase (AST)

	AST		
	All (n = 383)	Males (n = 199)	Females (n = 184)
CoQ ₁₀ [μmol/l]	0.086	0.093	0.044
Ubiquinol [μmol/l]	0.097	0.099	0.062
Ubiquinone [μmol/l]	0.028	0.042	0.003
CoQ ₁₀ redox state [%]	-0.084	-0.105	-0.049

[18]. Furthermore, several researchers have postulated that serum GGT activity, in its normal range, is a potential marker of oxidative stress [23-25]. It was shown in a longitudinal study that low circulating concentrations of several antioxidants (i.e., tocopherols, carotenoids) inversely predicted serum GGT concentrations ten years later [29]. Because CoQ₁₀ is a known antioxidant, one would expect decreased levels of antioxidative CoQ₁₀ or ubiquinol in the presence of high serum GGT activity. In the present study, there was a strong positive relationship between serum GGT activity and total CoQ₁₀, ubiquinol and ubiquinone in study subjects with normal serum GGT activity. As we examined the relationship between CoQ₁₀ status and serum GGT activity in a cross-sectional study, we were only able to examine one time point. Therefore, longitudinal studies should be conducted to elucidate the long-term relationship of serum CoQ₁₀ and serum GGT activity. Nevertheless, it is possible that serum GGT may be an activator of the antioxidative system in humans exposed to oxidative stress. If so, CoQ₁₀ might be the first antioxidant that is

synthesized or released due to elevated serum GGT activity. This hypothesis is supported by ideas from the CARDIA study. There, it was speculated that an increase of serum GGT might eventually minimize oxidative stress by facilitating antioxidative defense (i.e., GSH) [23].

In summary, there is a strong relationship between human CoQ₁₀ status and serum GGT activity. However, further investigations are needed to elucidate the complex relationship between antioxidant CoQ₁₀ and serum GGT as a potential marker of oxidative stress in more detail. For this purpose, additional specific and stable byproducts of oxidative damage to lipids, DNA or proteins in the blood should also be examined in future research.

Gender-specific differences in the association between CoQ₁₀ status and serum GGT activity

It is known that higher CoQ₁₀ levels as well as increased GGT activity are strongly associated with male gender [20,30,31]. This finding was confirmed in our study because men had higher levels of both CoQ₁₀ and serum GGT activity than women. Additionally, this fact explains the gender-specific differences regarding the strength of the correlation between serum GGT activity and CoQ₁₀ status in our study sample. The reasons for gender-related differences in CoQ₁₀ levels and serum GGT activity are most likely physiologic and based on hormonal differences between the genders. It was previously shown in females that the use of oral contraceptives increased GGT activity level by 15 percent and pregnancy lowered GGT activity level by 25 percent, whereas the postmenopausal state was associated with a 7 percent increase in GGT activity [32]. Similar hormonal relationships have been shown for CoQ₁₀ but in the opposite direction: women using oral contraceptives had lower levels of CoQ₁₀ compared to women who were not using hormonal contraceptives [33]. This finding is in accordance with other studies that have shown increased oxidative stress in women using oral contraceptives [34]. Based on these findings, we could possibly explain the strong association of the CoQ₁₀ redox state and serum GGT activity found in the women of our study. However, we do not know if our female study subjects were using oral contraceptives or other hormonal therapies. In future research, the hormonal status of female volunteers should be taken into account when

Table 4 Basic characteristics of cohort II (supplementation study)

	Males (n = 53)
Age [years]	30.1 ± 6.7
Body mass index [kg/m ²]	24.1 ± 2.5
CoQ ₁₀ [μmol/l]	0.96 ± 0.31
Ubiquinol [μmol/l]	0.89 ± 0.29
Ubiquinone [μmol/l]	0.07 ± 0.02
CoQ ₁₀ redox state [%]	7.5 ± 0.97
Gamma GT [U/l]	20.5 ± 10.4
C-reactive protein [mg/dl]	0.30 ± 0.01
systolic BP [mm Hg]	127 ± 12
Diastolic BP [mm Hg]	83 ± 9
Triglycerides [mg/dl]	97.4 ± 49.0
Cholesterol [mg/dl]	166.1 ± 29.8
LDL-cholesterol [mg/dl]	95.5 ± 28.9
HDL-cholesterol [mg/dl]	51.1 ± 12.9
Glucose [mg/dl]	86.5 ± 10.7

CoQ₁₀ = Coenzyme Q₁₀, Gamma GT = gamma glutamyltransferase; BP = blood pressure; LDL = low density lipoprotein, HDL = high density lipoprotein. Data are presented as mean ± SD.




Figure 3 The impact of Q₁₀H₂ supplementation on gamma glutamyltransferase (GGT, A) and GGT1 mRNA levels (B) as well as alanine aminotransferase (AST, C) and GOT2 mRNA levels (D). Data show respective effects before (T₀) and after (T₁₄) supplementation. Data are calculated from the mean (±SEM) of 53 (A + C) or rather three (B + D) volunteers. Bar graphs are presented as the mean ± SD, ***p < 0.001 significant differences between T₀ and T₁₄, paired Student's t-test.

investigating the relationship between serum CoQ₁₀ levels and serum GGT activity in women.

Relationship between serum CoQ₁₀ status and serum AST
Similar to GGT, AST is associated with oxidative stress and increased all-cause mortality [35,36]. In contrast to GGT, we did not find an association between CoQ₁₀ status and serum AST activity in our study. Therefore, we conclude that the association between GGT and CoQ₁₀ is specific and does not appear to generalize to other liver-related enzymes such as AST.

Supplementation study

The effect of Q₁₀H₂ supplementation on serum GGT/AST activity

CoQ₁₀ is a known modulator of gene expression [4,5] and inflammatory processes [7-9]. Because the reduced form of CoQ₁₀, ubiquinol, is a potent antioxidant that protects lipids, DNA and proteins from oxidative damage [12-14], we examined the effect of Q₁₀H₂ supplementation on both serum GGT and AST activity as potential markers of oxidative stress. Because we revealed an effect of Q₁₀H₂ supplementation on serum GGT activity but not on serum AST activity, we speculate that the effect of Q₁₀H₂ supplementation may be specific to serum GGT activity as a marker of oxidative

stress in men. Support for this hypothesis comes from the strong associations found in cohort I between CoQ₁₀ status and GGT activity but not between CoQ₁₀ status and serum AST activity. In contrast, Yuvaraj *et al.* examined the effect of CoQ₁₀ combined with riboflavin and niacin on serum GGT and serum AST in Tamoxifen-treated postmenopausal women with breast cancer [37] and found that the activity of both serum GGT and serum AST decreased in response to exogenous supplementation of CoQ₁₀, niacin and riboflavin. Although Yuvaraj and colleagues used CoQ₁₀ instead of ubiquinol and administered it in combination with niacin and riboflavin, the effect they found on serum AST might be due to a synergistic effect of all three antioxidative co-enzymes. Furthermore, they used a postmenopausal female study sample suffering from breast cancer whereas our study sample was male and healthy. Therefore, hormonal differences as well as disease status should be considered when examining the effects of Q₁₀H₂ supplementation on serum activity levels of liver-related enzymes (i.e., GGT, AST).

Effect of Q₁₀H₂ supplementation on GGT1/GOT2 mRNA level

Several studies have shown that oxidative stress, or rather instigators of oxidative stress (i.e., iron), lead to increased GGT mRNA as well as AST mRNA levels [35,38]. Here Q₁₀H₂ supplementation caused a transcriptional down regulation of

GGT1 mRNA and *GOT2* mRNA. The reduction in *GGT1* mRNA levels led to a decrease in serum GGT activity and a consequent decline in oxidative stress whereas the transcriptional down regulation of the *GOT2* gene caused no decline in serum AST activity.

In summary, Q₁₀H₂ reduced the activity of GGT as a marker of oxidative stress on protein and *GGT1* mRNA level in CD14-positive monocytes. Indeed, there is a need for further studies examining the effect of Q₁₀H₂ supplementation on *GGT1* mRNA levels in liver tissue. Nevertheless, our findings provide preliminary evidence that there might be an effect of ubiquinol supplementation on serum GGT activity. This effect might be caused by gene expression. Additionally, this supplementation effect seems to be specific to serum GGT activity, as supplementation did not affect the activity of other liver enzymes (i.e., AST).

Conclusions

There is a strong association between human CoQ₁₀ status and serum GGT activity. However, the strength of this association depends on gender and is more pronounced in men than women. In contrast, female but not male volunteers showed a strong association between the CoQ₁₀ redox state and serum GGT activity. Therefore, further studies are needed to examine the relationship between antioxidative CoQ₁₀ and serum GGT activity as a marker of oxidative stress in both males and females in more detail. Because Q₁₀H₂ supplementation led to a decrease in serum GGT activity as well as *GGT1* mRNA levels, we provide preliminary evidence that ubiquinol supplementation might improve oxidative stress on protein and gene expression levels. Further studies are needed to examine this effect in a larger cohort. Additionally, the effect of ubiquinol supplementation on *GGT1* mRNA levels should be further examined in organ tissue samples (i.e., liver).

Competing interests

The authors declare that they have no competing interest regarding the publication of this article.

Authors' contributions

SO analyzed the data, interpreted results, and drafted and wrote the manuscript. PN and TM carried out the CoQ₁₀ measurements. GJ, UN and WL were responsible for biobanking in data analysis. FD carried out the gene expression experiments and was responsible for the concept and design of the study, and drafting of the paper. All authors read and critically revised the final manuscript.

Acknowledgements

We thank all participants of the PopGen-control cohort study for their invaluable contribution to the study. The popgen 2.0 network is supported by a grant from the German Ministry for Education and Research (01EY1103). The whole study was supported by KANEKA Corporation, Japan.

Author details

¹Institute of Human Nutrition and Food Science, Division of Molecular Prevention, Christian Albrechts University Kiel, Heinrich-Hecht-Platz 10, 24118 Kiel, Germany. ²Children's Hospital of Datteln, University of Witten/Herdecke, Dr.-Friedrich-Steiner Str. 5, 45711 Datteln, Germany. ³Institute of Epidemiology and Biobank Popgen, Christian Albrechts University Kiel,

Campus University Hospital Schleswig-Holstein, Niemannsweg 11, Haus 1, 24105 Kiel, Germany. ⁴Institute of Nutrition and Food Science, Rheinische Friedrich Wilhelms University Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany.

Received: 27 February 2014 Accepted: 23 June 2014

Published: 4 July 2014

References

1. Crane FL: **Biochemical functions of coenzyme Q10.** *J Am Coll Nutr* 2001, **20**(6):591–598.
2. Lopez-Lluch G, Rodriguez-Aguilera JC, Santos-Ocana C, Navas P: **Is coenzyme Q a key factor in aging?** *Mech Ageing Dev* 2010, **131**(4):225–235.
3. Bentinger M, Tekle M, Dallner G: **Coenzyme Q—biosynthesis and functions.** *Biochem Biophys Res Commun* 2010, **396**(1):74–79.
4. Groneberg DA, Kindermann B, Althammer M, Klapper M, Vormann J, Littarru GP, Doring F: **Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells.** *Int J Biochem Cell Biol* 2005, **37**(6):1208–1218.
5. Schmelzer C, Doring F: **Identification of LPS-inducible genes downregulated by ubiquinone in human THP-1 monocytes.** *Biofactors* 2010, **36**(3):222–228.
6. Lee CK, Pugh TD, Klopp RG, Edwards J, Allison DB, Weindruch R, Prolla TA: **The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice.** *Free Radic Biol Med* 2004, **36**(8):1043–1057.
7. Schmelzer C, Lorenz G, Rimbach G, Doring F: **Influence of Coenzyme Q₁₀ on release of pro-inflammatory chemokines in the human monocytic cell line THP-1.** *Biofactors* 2007, **31**(3–4):211–217.
8. Schmelzer C, Lorenz G, Rimbach G, Doring F: **In Vitro Effects of the Reduced Form of Coenzyme Q(10) on Secretion Levels of TNF-alpha and Chemokines in Response to LPS in the Human Monocytic Cell Line THP-1.** *J Clin Biochem Nutr* 2009, **44**(1):62–66.
9. Schmelzer C, Lorenz G, Lindner I, Rimbach G, Niklowitz P, Menke T, Doring F: **Effects of Coenzyme Q10 on TNF-alpha secretion in human and murine monocytic cell lines.** *Biofactors* 2007, **31**(1):35–41.
10. Barroso MP, Gomez-Diaz C, Villalba JM, Buron MI, Lopez-Lluch G, Navas P: **Plasma membrane ubiquinone controls ceramide production and prevents cell death induced by serum withdrawal.** *J Bioenerg Biomembr* 1997, **29**(3):259–267.
11. Gonzalez R, Ferrin G, Hidalgo AB, Ranchal I, Lopez-Cillero P, Santos-Gonzalez M, Lopez-Lluch G, Briceno J, Gomez MA, Poyato A, Villalba JM, Navas P, de la Mata M, Muntané J: **N-acetylcysteine, coenzyme Q10 and superoxide dismutase mirmite prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes.** *Chem Biol Interact* 2009, **181**(1):95–106.
12. Crane FL, Navas P: **The diversity of coenzyme Q function.** *Mol Aspects Med* 1997, **18**(Suppl):S1–S6.
13. Ernster L, Dallner G: **Biochemical, physiological and medical aspects of ubiquinone function.** *Biochim Biophys Acta* 1995, **1271**(1):195–204.
14. Bentinger M, Brismar K, Dallner G: **The antioxidant role of coenzyme Q.** *Mitochondrion* 2007, **7**(Suppl):S41–S50.
15. Karp DR, Shimooku K, Lipsky PE: **Expression of gamma-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death.** *J Biol Chem* 2001, **276**(6):3798–3804.
16. Hanigan MH, Ricketts WA: **Extracellular glutathione is a source of cysteine for cells that express gamma-glutamyl transpeptidase.** *Biochemistry* 1993, **32**(24):6302–6306.
17. Courty C, Heisterkamp N, Siest G, Groffen J: **Expression of multiple gamma-glutamyltransferase genes in man.** *Biochem J* 1994, **297**(Pt 3):503–508.
18. Teschke R, Brand A, Strohmeyer G: **Induction of hepatic microsomal gamma-glutamyltransferase activity following chronic alcohol consumption.** *Biochem Biophys Res Commun* 1977, **75**(3):718–724.
19. Brenner H, Rothenbacher D, Arndt V, Schubert S, Fraisse E, Fliehdner TM: **Distribution, determinants, and prognostic value of gamma-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany.** *Prev Med* 1997, **26**(3):305–310.
20. Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, Steffes M: **Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.** *Clin Chem* 2003, **49**(8):1358–1366.

21. Jousilahti P, Rastenyte D, Tuomilehto J: **Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke.** *Stroke* 2000, **31**(8):1851–1855.
22. Perry LJ, Wannamethee SG, Shaper AG: **Prospective study of serum gamma-glutamyltransferase and risk of NIDDM.** *Diabetes Care* 1998, **21**(5):732–737.
23. Lee DH, Blomhoff R, Jacobs DR Jr: **Is serum gamma glutamyltransferase a marker of oxidative stress?** *Free Radic Res* 2004, **38**(6):535–539.
24. Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR Jr, Lee DH: **Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress?** *Free Radic Biol Med* 2004, **37**(7):1018–1023.
25. Lee DH, Lim JS, Yang JH, Ha MH, Jacobs DR Jr: **Serum gamma-glutamyltransferase within its normal range predicts a chronic elevation of alanine aminotransferase: a four year follow-up study.** *Free Radic Res* 2005, **39**(6):589–593.
26. Nothlings U, Krawczak M: **PopGen. A population-based biobank with prospective follow-up of a control group.** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2012, **55**(6–7):831–835.
27. Schmelzer C, Niklowitz P, Okun JG, Haas D, Menke T, Doring F: **Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans.** *IUBMB Life* 2011, **63**(1):42–48.
28. Menke T, Niklowitz P, Adam S, Weber M, Schluter B, Andler W: **Simultaneous detection of ubiquinol-10, ubiquinone-10, and tocopherols in human plasma microsomes and macrosamples as a marker of oxidative damage in neonates and infants.** *Anal Biochem* 2000, **282**(2):209–217.
29. Lee DH, Gross MD, Jacobs DR Jr: **Association of serum carotenoids and tocopherols with gamma-glutamyltransferase: the Cardiovascular Risk Development in Young Adults (CARDIA) Study.** *Clin Chem* 2004, **50**(3):582–588.
30. Kaikkonen J, Nyyssonen K, Tuomainen TP, Ristonmaa U, Salonen JT: **Determinants of plasma coenzyme Q10 in humans.** *FEBS Lett* 1999, **443**(2):163–166.
31. Miles MV, Horn PS, Morrison JA, Tang PH, DeGrauw T, Pesce AJ: **Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults.** *Clin Chim Acta* 2003, **332**(1–2):123–132.
32. Nilssen O, Forde OH, Brenn T: **The Tromso Study. Distribution and population determinants of gamma-glutamyltransferase.** *Am J Epidemiol* 1990, **132**(2):318–326.
33. Palan PR, Magnuson AT, Castillo M, Dunne J, Mikhail MS: **Effects of menstrual cycle and oral contraceptive use on serum levels of lipid-soluble antioxidants.** *Am J Obstet Gynecol* 2006, **194**(5):e35–e38.
34. Chen JT, Kotani K: **Oral contraceptive therapy increases oxidative stress in pre-menopausal women.** *Int J Prev Med* 2012, **3**(12):893–896.
35. Josekutty J, Iqbal J, Iwawaki T, Kohno K, Hussain MM: **Microsomal triglyceride transfer protein inhibition induces endoplasmic reticulum stress and increases gene transcription via Irf1alpha/cJun to enhance plasma ALT/AST.** *J Biol Chem* 2013, **288**(20):14372–14383.
36. Koehler EM, Sanna D, Hansen BE, van Rooij FJ, Heeringa J, Hofman A, Tiemeier H, Stricker BH, Schouten JN, Janssen HL: **Serum liver enzymes are associated with all-cause mortality in an elderly population.** *Liver Int* 2014, **34**(2):296–304.
37. Yuvaraj S, Premkumar VG, Shanthy P, Vijayasathy K, Gangadaran SG, Sachdanandam P: **Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles.** *Breast Cancer Res Treat* 2009, **114**(2):377–384.
38. Brown KE, Kinter MT, Oberley TD, Freeman ML, Frierson HF, Ridnour LA, Tao Y, Oberley LW, Spitz DR: **Enhanced gamma-glutamyl transpeptidase expression and selective loss of CuZn superoxide dismutase in hepatic iron overload.** *Free Radic Biol Med* 1998, **24**(4):545–555.

doi:10.1186/1756-0500-7-427

Cite this article as: Onur et al.: Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans. *BMC Research Notes* 2014 **7**:427.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

